Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2016-10-05 Regulatory Filings
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 5, 2016, reporting on two main events: entry into a material definitive agreement (a License Agreement with AstraZeneca) and an amended and restated loan and security agreement with Hercules Capital. The content focuses on contractual agreements and financing arrangements, typical of current reports on material events. There are no financial statements or comprehensive financial data presented, nor is this a transcript, proxy, or annual/interim report. The document is not a report publication announcement but the actual filing of a current report on material events. Therefore, the filing type corresponds to a Regulatory Filing (RNS) as a fallback category for SEC Form 8-K filings reporting material agreements and financing updates that do not fit other specific categories.
2016-10-05 English
PRIMARY DOCUMENT
Director's Dealing
2016-10-04 English
PRIMARY DOCUMENT
Director's Dealing
2016-10-04 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 27, 2016, reporting the appointment of a new Chief Commercial Officer, Mr. Roger Adsett. The content focuses on management changes, including details of the new officer's background, employment agreement, compensation, and stock options. There are no financial statements or earnings data presented. The primary subject is the change in senior management personnel. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). Therefore, this document is best classified as MANG.
2016-09-27 English
Regulatory Filings 2016
Regulatory Filings
2016-09-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 4, 2016, by Insmed Incorporated. It specifically references Item 2.02 - Results of Operations and Financial Condition, indicating it includes a press release about financial results for the three and six months ended June 30, 2016. The document states that the press release is furnished as an exhibit and is not considered filed for certain regulatory purposes. The length is 3111 characters, which is relatively short and the document mainly announces the release of financial results rather than containing detailed financial statements or analysis itself. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only.
2016-08-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.